Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duvivier

Showing results (421-430 of 505) with videos related to

Pageof 51
Sort By:
The Journal of Antimicrobial Chemotherapy|November 4, 2025
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational studyRomain Palich, Jade Ghosn, Karine Lacombe, et al.
Annals of Surgical Oncology|March 3, 2023
Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of LiteratureYasmin A Civil, Lysanne W Jonker, Maartje P M Groot Koerkamp, et al.
AIDS (London, England)|February 2, 2016
Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokersAlain Makinson, Sabrina Eymard-Duvernay, François Raffi, et al.
The Journal of Antimicrobial Chemotherapy|October 25, 2020
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimenRomain Palich, Clotilde Allavena, Gilles Peytavin, et al.
The Lancet. HIV|January 14, 2018
Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trialPatrick Mercié, Julie Arsandaux, Christine Katlama, et al.
Nature Communications|February 11, 2026
An Antarctic ecosystem value index to quantify ecological value across trophic levels and over timeAlice K DuVivier, Kristen M Krumhardt, Laura L Landrum, et al.
Plos One|April 25, 2019
"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort studyPierre Gantner, Babacar Sylla, Laurence Morand-Joubert, et al.
Orphanet Journal of Rare Diseases|August 5, 2024
Acid sphingomyelinase deficiency in France: a retrospective survival studyWladimir Mauhin, Nathalie Guffon, Marie T Vanier, et al.
BMC Infectious Diseases|March 27, 2019
Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohortC Lions, O Cabras, L Cotte, et al.
Ultrasound in Medicine & Biology|July 13, 2025
Multiparametric ultrasound evaluation of metabolic dysfunction-associated fatty liver disease in minipigsGeorges Chabouh, Basile Pradier, Louise Denis, et al.
Pageof 51

Showing results (421-430 of 505) with videos related to

Sort By:
Pageof 51
The Journal of Antimicrobial Chemotherapy|November 4, 2025
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational studyRomain Palich, Jade Ghosn, Karine Lacombe, et al.
Annals of Surgical Oncology|March 3, 2023
Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of LiteratureYasmin A Civil, Lysanne W Jonker, Maartje P M Groot Koerkamp, et al.
AIDS (London, England)|February 2, 2016
Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokersAlain Makinson, Sabrina Eymard-Duvernay, François Raffi, et al.
The Journal of Antimicrobial Chemotherapy|October 25, 2020
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimenRomain Palich, Clotilde Allavena, Gilles Peytavin, et al.
The Lancet. HIV|January 14, 2018
Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trialPatrick Mercié, Julie Arsandaux, Christine Katlama, et al.
Nature Communications|February 11, 2026
An Antarctic ecosystem value index to quantify ecological value across trophic levels and over timeAlice K DuVivier, Kristen M Krumhardt, Laura L Landrum, et al.
Plos One|April 25, 2019
"Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort studyPierre Gantner, Babacar Sylla, Laurence Morand-Joubert, et al.
Orphanet Journal of Rare Diseases|August 5, 2024
Acid sphingomyelinase deficiency in France: a retrospective survival studyWladimir Mauhin, Nathalie Guffon, Marie T Vanier, et al.
BMC Infectious Diseases|March 27, 2019
Missed opportunities of HIV pre-exposure prophylaxis in France: a retrospective analysis in the French DAT'AIDS cohortC Lions, O Cabras, L Cotte, et al.
Ultrasound in Medicine & Biology|July 13, 2025
Multiparametric ultrasound evaluation of metabolic dysfunction-associated fatty liver disease in minipigsGeorges Chabouh, Basile Pradier, Louise Denis, et al.
Pageof 51